Table II.

Summary of adverse events.

Adverse event (AE)	Arm A: rituximab (n = 40)	Arm B: rituximab + ABT-263 (n = 38)	Arm C: rituximab + ABT-263 to PD (n = 40)
Any SAEs, n (%)	5 (13)	5 (13)	4 (10)
Any AEs, n (%)	33 (87)	37 (97)	40 (100)
AEs grade ≥ 3 occurring in > 5% of patients, n (%)
Neutropenia	3 (8)	11 (29)	18 (45)
Thrombocytopenia	0 (0)	7 (18)	13 (33)
Anemia/worsening of anemia	2 (5)	2 (5)	1 (3)
Leukopenia	1 (3)	2 (5)	1 (3)
Liver enzyme increase	0 (0)	3 (8)	10 (25)
Hyperbilirubinemia	0 (0)	2 (5)	1 (3)
Diarrhea	0 (0)	2 (5)	1 (3)
GI and abdominal pain	0 (0)	0 (0)	2 (5)
Chills	0 (0)	2 (5)	1 (3)
Asthenia	0 (0)	2 (5)	0 (0)
Respiratory tract infection	3 (8)	1 (3)	1 (3)
Procedural complications (infusion-related reactions)	0 (0)	3 (8)	2 (5)
Vascular hypertensive disorders (hypertension)	0 (0)	2 (5)	1 (3)

SAE, serious adverse event; GI, gastrointestinal; PD, progressive disease.